Results 161 to 170 of about 3,056 (181)

Alzheimerdemenz mit Donanemab erheblich gebremst

DNP – Die Neurologie & Psychiatrie, 2023
openaire   +1 more source

Clinical Relevance of Donanemab Treatment

A Atri1, A Wessels2, E Doty2, A Atkins2, J Chandler2, Ming Lu2, W Ye2, E Dennehy2, D Brooks2, J Sims2, N Brookfield (Non-author Presenter)3   +9 more
openaire   +1 more source

Med Check: No Accelerated Pathway for Donanemab and More

Psychiatric News, 2023
openaire   +1 more source

FDA erteilt Donanemab Zulassung

psychopraxis. neuropraxis
openaire   +1 more source

Donanemab jetzt in Deutschland verfügbar

InFo Neurologie + Psychiatrie
openaire   +1 more source

Donanemab precautions revised in Japan

Reactions Weekly
openaire   +1 more source

Clinical Relevance of Donanemab Treatment (S1.004)

Neurology
Alireza Atri, Alette Wessels, Erin Doty, Alexandra Atkins, Julie Chandler, Ming Lu, Wenyu Ye, Ellen Dennehy, Dawn Brooks, John Sims   +9 more
openaire   +1 more source

Donanemab eligibility in early Alzheimer's disease: A real-world study

Journal of Alzheimer's Disease
Stefano Giannoni-Luza, Alessandro Introna, Daniele Urso   +2 more
exaly  

Donanemab for Alzheimer’s disease: from preclinical research to the clinical application

Expert Review of Neurotherapeutics
Richard Dodel
exaly  

Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis

Ageing Research Reviews
Itsuki Terao, Wakako Kodama
exaly